AZD7648 for Cancer

"This trial is recruiting individuals aged 18-130."

"AZD7648 was first studied in 1997 at the Spectrum Health Butterworth Campus, and since then 678 clinical trials have been completed. At present there are 360 active studies worldwide, with a concentration of research occurring in New Haven, Connecticut."

"At this time, enrollment for the referenced study is closed. Originally posted on October 9th 2019 and last edited November 9th 2022, other options exist with 2376 trials recruiting patients suffering from advanced forms of cancer and 360 studies enrolling participants taking AZD7648 as a treatment option."

"This clinical trial has two primary objectives. The first is to measure the number of participants with adverse events/serious adverse events over each 28-day cycle, and the second is to characterise AZD7648's pharmacokinetics when given monotherapy or alongside anti-cancer agents by measuring AUC from zero to last measurable concentration (AUCtau), time to reach maximum plasma concentration (Tmax) and progression-free survival (PFS)."

"Data published on clinicaltrials.gov reveals that this particular medical trial, which began recruitment in October 2019 and ended in November 2022 is no longer accepting applicants. However, a plethora of other trials (2736 to be exact) are still recruiting patients at present."

"To qualify for this medical experiment, participants should possess an advanced form of cancer and be between 18 to 130 years old. A maximum of 30 volunteers will be accepted."

"Alfacell first initiated the clinical trials for AZD7648 in 1997, which included 300 participants. Consequently, after successful Phase 3 approval was granted to AZD7648 and as of today, 66 countries across 1941 cities are running 360 active studies related to this medication."

"AZD7648 has been successfully employed to treat various forms of cancer, including lymphoma, Hodgkin's disease, bronchogenic carcinoma and neuroblastoma."